Miskolc, Hungary Clinical Trials

A listing of Miskolc, Hungary clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 75 clinical trials
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can …

cancer
lung carcinoma
measurable disease
lung cancer
breast cancer
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
 (1.4 away) Contact site
  • 0 views
  • 15 Jul, 2021
  • +198 other locations
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833 PF-06651600 AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.

rheumatism
tofacitinib
methotrexate
high sensitivity
erythrocyte sedimentation
Huniko Kereskedelmi s Eg szs g gyi Szolg ltat Kft.
 (0.3 away) Contact site
  • 17 views
  • 28 Jul, 2021
  • +180 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

cancer
fluorouracil
metastatic bladder carcinoma
pembrolizumab
gemcitabine
BAZ Megyei Korhaz. Klinikai Onkologia es Sugarterapias Centrum ( Site 0092)
 (1.4 away) Contact site
  • 76 views
  • 28 Jul, 2021
  • +111 other locations
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

anticoagulation therapy
fibrillation
stroke
rivaroxaban
vascular disease
Anthos Investigative Site
 (1.4 away) Contact site
  • 0 views
  • 28 Jul, 2021
  • +52 other locations
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept injections in subjects with newly diagnosed neovascular age-related macular degeneration (nAMD).

age-related macular degeneration
fibrosis
glaucoma
photocoagulation
spectral domain optical coherence tomography
Jahn Ferenc D l-pesti K rh z (Jahn Ferenc South-Pest Hospital)
 (90.5 away) Contact site
  • 7 views
  • 28 Jul, 2021
  • +39 other locations
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response …

cancer
mk-3475
pembrolizumab
squamous cell carcinoma
measurable disease
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 2203)
 (1.4 away) Contact site
  • 15 views
  • 28 Jul, 2021
  • +146 other locations
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.

Research Site
 (1.4 away) Contact site
  • 0 views
  • 28 Jul, 2021
  • +153 other locations
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.

ileal disease
abdominal pain
immunomodulators
corticosteroids
crohn's disease
CRU Hungary Kft
 (0.8 away) Contact site
  • 397 views
  • 12 Mar, 2021
  • +387 other locations
A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.

plaque psoriasis
etanercept
arthritis
varicella
guselkumab
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
 (1.4 away) Contact site
  • 51 views
  • 20 Jun, 2021
  • +49 other locations
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

crohn's disease
remission
CRU Hungary Kft
 (0.8 away) Contact site
  • 1032 views
  • 22 Feb, 2021
  • +807 other locations